WASHINGTON, DC—Retail prices for many of the most commonly-used brand name drugs by older adults rocketed upward by an average of 8.4 percent in 2017, outstripping the general inflation rate of 2.1 percent. The annual average cost of therapy for just one brand name drug increased to almost $6,800 in 2017.

WASHINGTON, DC—AARP Executive Vice President and Chief Advocacy & Engagement Officer Nancy LeaMond released the following statement in response to lobbying efforts by PhRMA to change the Medicare Part D doughnut hole deal

WASHINGTON, DC—Information stolen in computer breaches of well-known companies is flooding into an underground digital market called the Dark Web, where criminals buy and sell Social Security numbers, credit card information and computer passwords to be used for fraud, an investigation in the September issue of AARP Bulletin reveals. Using software originally developed by the U.S. Navy and available for free to anyone who wishes to download it, criminals buy and sell private data with complete anonymity, then use it to commit identity fraud. Approximately 6.6 percent of U.S. adults were victimized last year, the report shows, and allegedly, more than half of Americans’ Social Security numbers are for sale for as low as a few dollars each. The article also details how identity fraud typically occurs, and the many proven, powerful ways consumers can protect themselves.

WASHINGTON, D.C.—A majority (70 percent) of elderly dementia patients prescribed dementia drugs are on them long-term despite the lack of evidence that they provide any benefit beyond one year, according to a new report by AARP Public Policy Institute. The study found that some patients took dementia drugs for as long as a decade, costing as much as $20,000 per patient.

WASHINGTON, D.C.—Today AARP CEO Jo Ann Jenkins released a statement in reaction to the news of music legend Aretha Franklin’s passing.

WASHINGTON, DC—On June 25, AARP announced an unprecedented investment of $60 million in the Dementia Discovery Fund (DDF) the first and largest venture fund focused on discovering and developing effective new drugs for treating dementia and ultimately a cure. Now, a special report in the July/August issue of AARP Bulletin details the scope of this healthcare issue, provides a profile of DDF, and explains why research to date has yielded so few solutions, despite tens of billions of dollars being spent.

WASHINGTON, D.C. — AARP announced today the launch of “An AARP Take on Today,” a weekly podcast hosted by Bob Edwards, the original and longtime host of NPR’s flagship program “Morning Edition.” Each new episode will feature in-depth news interviews on timely topics with guest experts on health, work, money, aging, entertainment and more.

WASHINGTON, DC—With nearly 10 million new cases of dementia and Alzheimer’s disease occurring each year1, and no cure, today AARP launched a new campaign, “Disrupt Dementia.” The campaign...

WASHINGTON, DC—Today, AARP and AARP Foundation have asked the U.S. District Court to accept an amicus brief supporting the constitutionality of the Patient Protection and Affordable Care Act (ACA). The brief explains many ways in which the ACA has greatly benefited older adults and emphasizes the importance of protections for people with preexisting conditions and the limits on charging higher rates based on age (age tax). AARP and AARP Foundation have requested that the court accept the brief in response to the state of Texas’ request for a preliminary injunction to stop implementation of the ACA.

WASHINGTON, DC—AARP Executive Vice President and Chief Advocacy & Engagement Officer Nancy LeaMond released the following statement in response to President Trump’s address today on prescription drug prices: